Bremelanotide Acetate (PT-141)
Brief Introduction:
PT-141 (Bremelanotide) is a synthetic peptide drug that acts as an analog of α-melanocyte stimulating hormone (α-MSH) by activating melanocortin receptors (MCR).
Bremelanotide is mainly used to study and treat female sexual dysfunction, especially hypoactive sexual desire disorder.
In clinical trials, Bremelanotide showed significant effects on premenopausal women with hypoactive sexual desire disorder and helped them maintain normal sexual desire.
Sequence:
Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH (Chemical Bridge Asp2-Lys7)
Mechanism of Action:
PT-141 acts directly on the central nervous system, especially the hypothalamus and limbic system's sexual behavior regulatory areas (such as mPOA), by non-selectively activating melanocortin receptor subtypes (such as MC3R and MC4R), thereby regulating sexual desire and sexual response.
Unlike traditional drugs (such as Sildenafil), it does not rely on peripheral vasodilation, but works through neural pathways.
Clinical Applications:
▲★ Indications:
Mainly used to treat female hypoactive sexual desire disorder (HSDD), especially premenopausal women. It was approved by the US FDA on June 21st, 2019, with the trade name Vyleesi®, and the dosage form is subcutaneous injection.
▲★ Efficacy Characteristics:
Clinical trials show that its efficacy peaks about 4 hours after injection, can quickly stimulate sexual desire, and is non-addictive.
▲★ Other Studies:
Early studies also explored its potential role in male sexual dysfunction, but the main indications are concentrated in the female population.
Specifications of our PT-141:
| Test Items | Specifications | |
| Appearance | White powder | |
| Solubility (Water) | Not less than 5mg/mL | |
| MS (ESI) | 1025.16 ± 1.0 | |
| Purity (HPLC) | Not less than 98.0% | |
| Related Substances (HPLC) | Any individual impurity: ≤1.0% | |
| Peptide Content (N%) | Not less than 80.0% | |
| Water Content (Karl Fischer) | Not more than 10.0% | |
| Amino Acid Analysis | His | 0.8 ~ 1.2 |
| Asp | 0.8 ~ 1.2 | |
| Arg | 0.8 ~ 1.2 | |
| Lys | 0.8 ~ 1.2 | |
| Phe | 0.8 ~ 1.2 | |
| Trp | 0.8 ~ 1.2 | |
| Acetate Content (HPLC) | Less than 12.0% | |
| TFA Content | Not more than 0.5% | |
| Residual Solvents (GC) | Acetonitrile | Not more than 410ppm |
| Methanol | Not more than 3000ppm | |
| Ether | Not more than 5000ppm | |
| Methylene Chloride | Not more than 600ppm | |
| N,N-Dimethylformamide | Not more than 880ppm | |
| Triisopropylsilane | Not more than 5000ppm | |
| Bacterial endotoxins | Less than 10EU/mg | |
| Microbial Limits | Total aerobic microbial count | Not more than 200CFU/g |
| Total yeast and mold count | Not more than 200CFU/g | |
| Assay (HPLC) | 95.0% ~ 105.0% (On the anhydrous, acetic acid-free basis) | |
Laboratory & Equipment Display:
Packaging:
① Raw Powder: 1g/Bottle, 2g/Bottle, 3g/Bottle, 5g/Bottle or according to the specific requirements from customers.
② Lyophilized Powder: 10 Vials per Box (10mg per Vial).
Minimum Order Quantity (MOQ):
① Raw Powder: 1 gram.
② Lyophilized Powder: One Box (10mg*10vials).
Payment Methods:
Modes of Transport:
Storage Conditions:
① Raw Powder:
Stored in a cool dry place away from sunlight and moisture (Recommended temperature: below -20℃).
② Lyophilized Powder:
Preserved in air tight containers, protected from light (Recommended temperature: -25℃ ~ -15℃).
Shelf Life:
24 months from the date of manufacturing when stored under the above mentioned conditions.
